Isabelle Lessard1, Caroline Lavoie2, Isabelle Côté2, Jean Mathieu1, Bernard Brais3, Cynthia Gagnon4. 1. Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN), Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-St-Jean, Québec, Canada; Centre de recherche Charles-Le-Moyne, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada. 2. Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN), Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-St-Jean, Québec, Canada. 3. Montreal Neurological Institute, McGill University, Québec, Canada. 4. Groupe de recherche interdisciplinaire sur les maladies neuromusculaires (GRIMN), Centre intégré universitaire de santé et de services sociaux du Saguenay-Lac-St-Jean, Québec, Canada; Centre de recherche Charles-Le-Moyne, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Québec, Canada. Electronic address: cynthia.gagnon4@usherbrooke.ca.
Abstract
OBJECTIVE: Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neuromuscular disease leading to several impairments, including decrease of lower limb coordination. The Lower Extremity Motor Coordination Test (LEMOCOT) is an outcome measure recently developed for stroke population. The aim of this study was to document: 1) intra- and interrater reliability; 2) the standard error of measurement and minimal detectable change; and 3) the construct validity of the measurements obtained with the LEMOCOT in the adult ARSACS population. RESULTS: The LEMOCOT has shown a good intra- and interrater reliability with an intraclass correlation coefficient ranging from 0.92 to 0.97 for both dominant and non-dominant side. The construct validity (hypothesis testing) is satisfying where LEMOCOT's score negatively correlated with participants' age (r=-0.74) and the score of the Scale for the Assessment and Rating of Ataxia (r=-0.86) and positively correlated with the balance and mobility tests (r=0.82 with the Berg Balance Scale, r=0.61 with the Six-Minute Walk Test, r=0.57 with the 10-Meter Walk Test). The LEMOCOT was also able to distinguish between patients according to disease stages. CONCLUSION: The LEMOCOT is a valid and reliable tool to assess lower limb coordination in the ARSACS population for whom the lack of coordination is a common symptom.
OBJECTIVE:Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is a neuromuscular disease leading to several impairments, including decrease of lower limb coordination. The Lower Extremity Motor Coordination Test (LEMOCOT) is an outcome measure recently developed for stroke population. The aim of this study was to document: 1) intra- and interrater reliability; 2) the standard error of measurement and minimal detectable change; and 3) the construct validity of the measurements obtained with the LEMOCOT in the adult ARSACS population. RESULTS: The LEMOCOT has shown a good intra- and interrater reliability with an intraclass correlation coefficient ranging from 0.92 to 0.97 for both dominant and non-dominant side. The construct validity (hypothesis testing) is satisfying where LEMOCOT's score negatively correlated with participants' age (r=-0.74) and the score of the Scale for the Assessment and Rating of Ataxia (r=-0.86) and positively correlated with the balance and mobility tests (r=0.82 with the Berg Balance Scale, r=0.61 with the Six-Minute Walk Test, r=0.57 with the 10-Meter Walk Test). The LEMOCOT was also able to distinguish between patients according to disease stages. CONCLUSION: The LEMOCOT is a valid and reliable tool to assess lower limb coordination in the ARSACS population for whom the lack of coordination is a common symptom.
Authors: Cynthia Gagnon; Olivier Lambercy; Christoph M Kanzler; Isabelle Lessard; Roger Gassert; Bernard Brais Journal: Ann Clin Transl Neurol Date: 2022-02-27 Impact factor: 4.511